New Delhi: Pharma major Lupin said the UK health regulator has completed the inspection of its Goa facility without making any critical observations.
In a BSE filing, Lupin “announced the successful completion of the inspection by the UK MHRA at its Goa facility in March 2018. There were no critical or major observations in the inspections”.
“We are committed to maintaining truly global quality standards at our manufacturing units. The successful inspection by UK MHRA is a meaningful development for our Goa plant,” Lupin Managing Director Nilesh Gupta said.
Lupin had announced that its Pithampur unit 2 manufacturing facility located in Indore had been cleared by Health Canada after a review.
In November 2017, Lupin had received a warning letter from US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore.